Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 29, 2018 - Issue 8
Submit an article Journal homepage
2,532
Views
9
CrossRef citations to date
0
Altmetric
Oncology

Healthcare resource utilization, costs of care, and treatment of mycosis fungoides cutaneous T-cell lymphoma patterns in a large managed care population: a retrospective US claims-based analysis

Yuen TsangActelion, Inc, San Francisco, CA, USA; View further author information
,
Tao GuHealthCore, Inc, Wilmington, DE, USAView further author information
,
Gaurav SharmaActelion, Inc, San Francisco, CA, USA; View further author information
,
Susan RaspaActelion, Inc, San Francisco, CA, USA; View further author information
,
Bill Drake IIIActelion, Inc, San Francisco, CA, USA; View further author information
&
Hiangkiat TanHealthCore, Inc, Wilmington, DE, USACorrespondence[email protected]
View further author information
Pages 747-753 | Received 30 Jan 2018, Accepted 06 Apr 2018, Published online: 07 May 2018

References

  • Litvinov IV, Tetzlaff MT, Rahme E, et al. Demographic patterns of cutaneous T-cell lymphoma incidence in Texas based on two different cancer registries. Cancer Med. 2015;4:1440–1447.
  • Scarisbrick JJ, Kim YH, Whittaker SJ, et al. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sezary syndrome: where are we now? Br J Dermatol. 2014;170:1226–1236.
  • Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768–3785.
  • Quaglino P, Pimpinelli N, Berti E, et al. Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: a multicenter, retrospective follow-up study from the Italian group of cutaneous lymphomas. Cancer. 2012;118:5830–5839.
  • Pope E, Weitzman S, Ngan B, et al. Mycosis fungoides in the pediatric population: report from an international childhood registry of cutaneous lymphoma. J Cutan Med Surg. 2010;14:1–6.
  • Diamandidou E, Colome M, Fayad L, et al. Prognostic factor analysis in mycosis fungoides/Sézary syndrome. J Am Acad Dermatol. 1999;40:914–924.
  • Diamandidou E, Colome-Grimmer M, Fayad L, et al. Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. Blood. 1998;92:1150–1159.
  • Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Arch Dermatol. 2007;143:854–859.
  • Buzzell RA. Carcinogenesis of cutaneous malignancies. Dermatol Surg. 1996;22:209–215.
  • Wilson LD, Hinds GA, Yu JB. Age, race, sex, stage, and incidence of cutaneous lymphoma. Clin Lymphoma Myeloma Leuk. 2012;12:291–296.
  • Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66:443–459.
  • Trautinger F, Knobler R, Willemze R, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer. 2006;42:1014–1030.
  • Whittaker SJ, Marsden JR, Spittle M, British Association of D, Group UKCL, et al. Joint British association of dermatologists and U.K. Cutaneous Lymphoma group guidelines for the management of primary cutaneous T-cell lymphomas. Br J Dermatol. 2003;149:1095–1107.
  • Horwitz SM, Olsen EA, Duvic M, et al. Review of the treatment of mycosis fungoides and sezary syndrome: a stage-based approach. J Natl Compr Canc Netw. 2008;6:436–442.
  • Duarte RF, Canals C, Onida F, et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sezary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. JCO. 2010;28:4492–4499.
  • Prince HM. Are we close to a prognostic index for cutaneous T cell lymphoma? Leuk Lymphoma. 2014;55:7–8.
  • Demierre MF, Gan S, Jones J, et al. Significant impact of cutaneous T-cell lymphoma on patients’ quality of life: results of a 2005 National Cutaneous Lymphoma Foundation Survey. Cancer. 2006;107:2504–2511.
  • Demierre MF, Tien A, Miller D. Health-related quality-of-life assessment in patients with cutaneous T-cell lymphoma. Arch Dermatol. 2005;141:325–330.
  • Ricci E, Cortelazzo S, Krulichova I, et al. Direct medical costs of mycosis fungoides in specialized Italian hospital departments. Haematologica. 2005;90:270–272.
  • Wasser T, Wu B, Ycas J, et al. Applying weighting methodologies to a commercial database to project US census demographic data. Am J Account Care. 2015;3:33–38.
  • United States Department of labor. Consumer Price Index. Available at: https://www.bls.gov/cpi/ [cited 13 Nov 2017].
  • Poligone B, Heald P. Menus for managing patients with cutaneous T-cell lymphoma. Semin Cutan Med Surg. 2012;31:25–32.
  • Zic JA. Controversies in the management of the cutaneous T cell lymphomas. Dermatol Ther. 2009;22:407–417.
  • Latkowski JA, Heald P. Strategies for treating cutaneous T-cell lymphoma: part 1: remission. J Clin Aesthet Dermatol. 2009;2:22–27.
  • Suchin KR, Cucchiara AJ, Gottleib SL, et al. Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution. Arch Dermatol. 2002;138:1054–1060.
  • VALCHLOR Prescribing Information. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/20231-7lbl.pdf [cited 16 Nov 2017].

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.